Interferon-Beta Increases Plasma Ceramides of Specific Chain Length in Multiple Sclerosis Patients, Unlike Fingolimod or Natalizumab

Fingolimod is used for the treatment of multiple sclerosis (MS) and targets receptors for the bioactive sphingolipid sphingosine-1-phosphate (S1P). Whether fingolimod or other MS therapies conversely affect plasma concentrations of sphingolipids has, however, not yet been analyzed. Herein, we quanti...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Pharmacol
Main Authors: Ottenlinger, Florian M., Mayer, Christoph A., Ferreirós, Nerea, Schreiber, Yannick, Schwiebs, Anja, Schmidt, Katrin G., Ackermann, Hanns, Pfeilschifter, Josef M., Radeke, Heinfried H.
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2016
Assuntos:
Pharmacology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5093125/
https://ncbi.nlm.nih.gov/pubmed/27857690
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2016.00412
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados